|
|
|
|
| LEADER |
05224nam a2200577 4500 |
| 001 |
ocn936379407 |
| 003 |
OCoLC |
| 005 |
20180501122029.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
160202s2016 maua ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d IDEBK
|d YDXCP
|d EBLCP
|d N$T
|d OPELS
|d CDX
|d OCLCF
|d UAB
|d OCLCQ
|d MEU
|d GrThAP
|
| 019 |
|
|
|a 939262236
|
| 020 |
|
|
|a 9780128052112
|q electronic bk.
|
| 020 |
|
|
|a 0128052112
|q electronic bk.
|
| 020 |
|
|
|a 9780128047958
|
| 020 |
|
|
|a 012804795X
|
| 035 |
|
|
|a (OCoLC)936379407
|z (OCoLC)939262236
|
| 050 |
|
4 |
|a RM301.3.G45
|
| 050 |
|
4 |
|a QD431
|b .A3 v.102eb
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.7
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Personalized Medicine /
|c edited by Rossen Donev.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Waltham, MA :
|b Academic Press is an imprint of Elsevier,
|c 2016.
|
| 300 |
|
|
|a 1 online resource (xiii, 384 pages :
|b illustrations).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in protein chemistry and structural biology ;
|v volume 102
|
| 546 |
|
|
|a Text in English.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed February 9, 2016)
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 520 |
|
|
|a The Advances in Protein Chemistry and Structural Biology series is an essential resource for protein chemists. Each volume brings forth new information about protocols and analysis of proteins, with each thematically organized volume guest edited by leading experts in a broad range of protein-related topics.
|
| 505 |
0 |
|
|a Front Cover; Personalized Medicine; Copyright; Contents; Contributors; Preface; Chapter One: High-Performance Affinity Chromatography: Applications in Drug-Protein Binding Studies and Personalized Medicine; 1. Introduction; 1.1. Drug-Protein Interactions in Blood; 1.2. Preparation of HPAC Columns for Drug-Protein Binding Studies; 2. Frontal Analysis Studies of Drug-Protein Interactions; 2.1. General Principles of Frontal Analysis; 2.2. Characterization of Simple Interactions by Frontal Analysis; 2.3. Characterization of Complex Interactions by Frontal Analysis
|
| 505 |
8 |
|
|a 3. Zonal Elution Studies of Drug-Protein Interactions3.1. General Principles of Zonal Elution; 3.2. Characterization of Drug-Protein Interactions by Zonal Elution; 4. Other Methods for Examining Drug-Protein Interactions; 4.1. Peak Decay Method; 4.2. Ultrafast Affinity Extraction; 4.3. Chromatographic Immunoassays; 5. Conclusion; Acknowledgments; References; Chapter Two: Role of Proteomics in the Development of Personalized Medicine; 1. Introduction; 2. Protein Biomarkers; 2.1. Proteomic Technologies for Discovery of Biomarkers; 3. Protein Biochips
|
| 505 |
8 |
|
|a 3.1. Role of Protein Biochips in Personalized Medicine3.2. Nanoproteomics; 4. Role of Proteomics-Based Molecular Diagnostics in Personalized Medicine; 4.1. Integration of Diagnostics with Therapeutics; 5. Pharmacoproteomics; 5.1. Pharmacoproteomics and Personalized Medicine; 6. Concluding Remarks About Application of Proteomics for Personalized Medicine; References; Chapter Three: Metabolomics and Personalized Medicine; 1. Introduction; 2. The Value of ``Omics ́́Technologies in the Development of Personalized Medicine; 3. What is Metabolomics?
|
| 505 |
8 |
|
|a 3.1. Analytical Methods Most Often Used for Metabolomics3.2. Statistical Approaches; 4. The Application of Metabolomics Toward Personalized Medicine; 4.1. Identification of Disease Biomarkers for Metabolomics-Based Diagnostics; 4.2. Pharmacometabonomics; 4.2.1. Metabolomics and the Elucidation of Drug Mechanisms; 4.2.2. Metabolomics and Understanding Response to Treatment; 4.2.3. Metabolomics and Understanding Drug Toxicology; 5. Concluding Remarks; Acknowledgments; References; Chapter Four: Clinical Perspectives on Targeting Therapies for Personalized Medicine; 1. Introduction
|
| 505 |
8 |
|
|a 2. What Are Personalized Medicines?3. Rare Diseases; 4. Evidence for Precision Medicines from Real World Data; 5. Using ``Real World ́́Data; 6. Ethical Concerns; 7. Adaptive Trial Design; 8. Companion Diagnostics; 9. Biological Treatments; 10. Case Studies: Targets for Precision Medicines and Companion Diagnostics; 10.1. Drug Transporter Proteins; 10.2. Pleiotropic Effects of Statins; 10.3. Flecainide: Potential Off-Target Mechanism for Sudden Death; 10.4. EGF Receptor 2 Antagonism with Trastuzmab; 10.5. Diagnostic Markers to Guide Selection of Anti-cancer Tyrosine Kinase Receptor Inhibitors
|
| 650 |
|
0 |
|a Pharmacogenetics.
|
| 650 |
|
0 |
|a Medical care.
|
| 650 |
|
7 |
|a MEDICAL / Pharmacology
|2 bisacsh
|
| 650 |
|
7 |
|a Medical care.
|2 fast
|0 (OCoLC)fst01013753
|
| 650 |
|
7 |
|a Pharmacogenetics.
|2 fast
|0 (OCoLC)fst01060243
|
| 655 |
|
4 |
|a Electronic books.
|
| 655 |
|
0 |
|a Electronic books.
|
| 700 |
1 |
|
|a Donev, Rossen,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Donev, Rossen
|t Personalized medicine
|d : Elsevier Science,c2016
|z 9780128047958
|
| 830 |
|
0 |
|a Advances in protein chemistry and structural biology ;
|v v. 102.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/18761623/102
|z Full Text via HEAL-Link
|
